Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.52), $0.07 worse than the analyst estimate of ($0.45).

• PDUFA Target Action Date of July 19, 2017 for the DEXTENZA™ NDA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.